Respiratory syncytial virus aka RSV (Beyfortus™)

• Infants upto 8 months of age born October – March in most of the continental United States*
  • Mother did not receive RSV vaccine OR mother’s RSV vaccination status is unknown: 1 dose within 1 week of birth
  • Mother received RSV vaccine less than 14 days prior to delivery:1 dose within 1 week of birth 
  • Mother received RSV vaccine at least 14 days prior to delivery: nirsevimab not needed*
• Infants 8 months of age born April–September in most of the continental United States*
  • Mother did not receive RSV vaccine OR mother’s RSV vaccination status is unknown: 1 dose shortly before start of RSV season*
  • Mother received RSV vaccine less than 14 days prior to delivery: 1 dose shortly before start of RSV season*
  • Mother received RSV vaccine at least 14 days prior to delivery: not needed*

 

• Ages 8–19 months with chronic lung disease of prematurity requiring medical support (e.g., chronic corticosteroid therapy, diuretic therapy, or supplemental oxygen) any time during the 6-month period before the start of the second RSV season; severe immunocompromise; cystic fibrosis with either weight for length <10th percentile or manifestation of severe lung disease (e.g., previous hospitalization for pulmonary exacerbation in the first year of life or abnormalities on chest imaging that persist when stable)**:
  • 1 dose shortly before start of second RSV season*
• Ages 8–19 months who are American Indian or Alaska Native:
  • 1 dose shortly before start of second RSV season*
• Age-eligible and undergoing cardiac surgery with cardiopulmonary bypass**: 1 additional dose  after surgery. For additional details see special populations and situations at www.cdc.gov/vaccines/vpd/rsv/hcp/child-faqs.html

*Note: While the timing of the onset and duration of RSV season may vary, nirsevimab may be administered October through March in most of the continental United States. Providers in jurisdictions with RSV seasonality that differs from most of the continental United States (e.g., Alaska, jurisdiction with tropical climate) should follow guidance from public health authorities (e.g., CDC, health departments) or regional medical centers on timing of administration based on local RSV seasonality. Although optimal timing of administration is just before the start of the RSV season, nirsevimab may also be administered during the RSV season to infants and children who are age-eligible.